Ryan Cross

Twen­ty years ago, Lau­ra Nikla­son found­ed a com­pa­ny that sound­ed like some­thing out of sci­ence fic­tion. The Duke Uni­ver­si­ty bio­engi­neer and anes­the­si­ol­o­gist was work­ing in

The promise of a one-and-done CRISPR in­fu­sion is be­gin­ning to look more re­al than ever.On Thurs­day, In­tel­lia Ther­a­peu­tics an­nounced that an ex­per­i­men­tal gene edit­ing …

Pfiz­er is deep­en­ing its in­vest­ment in pro­tein de­graders through a new part­ner­ship with Tri­ana Bio­med­i­cines, a start­up work­ing in the trendy field of mol­e­c­u­lar glues

Viz­gen and Ul­tivue, two com­pa­nies at the fore­front of de­vel­op­ing tech­nolo­gies that al­low sci­en­tists to map the mol­e­c­u­lar make­up of cells in ex­quis­ite de­tail, are

If all goes ac­cord­ing to plan, in­sitro could fi­nal­ly start test­ing its first drug in clin­i­cal tri­als in 2026, eight years af­ter Daphne Koller found­ed